Comparative Pharmacology
Head-to-head clinical analysis: MYQORZO versus PRALUENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYQORZO versus PRALUENT.
MYQORZO vs PRALUENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myqorzo (selinexor) is a selective inhibitor of nuclear exportin 1 (XPO1). It binds to and inhibits XPO1, leading to nuclear retention and activation of tumor suppressor proteins, reduction in oncoprotein levels, and cell cycle arrest and apoptosis in cancer cells.
Praluent (alirocumab) is a human monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting PCSK9 binding to the low-density lipoprotein receptor (LDLR), it prevents PCSK9-mediated LDLR degradation, thereby increasing the number of LDLRs available on hepatocyte surfaces to clear LDL-C from the blood.
100 mg intravenous every 28 days
Praluent (alirocumab) is administered subcutaneously at a dose of 75 mg every 2 weeks. If additional LDL-C lowering is needed, the dose may be increased to 150 mg every 2 weeks or 300 mg every 4 weeks. The starting dose is 75 mg every 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 18-24 hours in patients with normal renal function. This supports once-daily dosing and allows for trough concentration monitoring.
Terminal half-life: 17–20 days. Supports every 2-week or every 4-week subcutaneous dosing.
Primarily renal excretion as unchanged drug (approx. 70-80%), with about 10-15% eliminated in feces via biliary excretion. Less than 5% is metabolized.
Degraded into small peptides and amino acids via proteolytic catabolism; no significant renal or biliary excretion of intact drug.
Category C
Category C
Antihyperlipidemic
Antihyperlipidemic